May 4, 2018 – A drug pricing initiative expected from the White House May 8 is likely to include a number of incremental steps on drug pricing to support a strategy that is trickling down from President Trump to Health & Human Services Secretary Alex Azar and FDA Commissioner Scott Gottlieb, M.D. This initiative may […]
Read moreFeb. 8, 2016 – At last week’s House hearing on drug pricing a bipartisan group of U.S. Congressional members, the press and much of the biopharma industry were focused on a public hanging of former Turing Pharmaceuticals CEO Martin Shkreli while the FDA offered quiet but compelling testimony on generic drug approvals. Although the FDA […]
Read more